Comparison

ABBOTT LABORATORIES (ABT) vs BOSTON SCIENTIFIC CORP (BSX)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

ABT

ABBOTT LABORATORIES

Medical Devices

Revenue, FY25: $44.33B
Net income: $6.52B
Operating cash flow: $9.57B
Free cash flow: $7.4B
Net margin: 14.72%
Operating margin: 18.17%
Gross margin: 56.42%

BSX

BOSTON SCIENTIFIC CORP

Medical Devices

Revenue, FY25: $20.07B
Net income: $2.89B
Operating cash flow: $4.53B
Free cash flow: $3.66B
Net margin: 14.41%
Operating margin: 18.00%
Gross margin: 69.01%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	ABT	BSX
Revenue growth, latest filed year	+5.67%	+19.87%
Piotroski F-score	6 of 9	7 of 9
P/E against its own history	15.41% below	71.57% below

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

ABT

Currency moves
Cybersecurity
Product recalls
FDA approval
Litigation
Supply chain

And 15 more.

BSX

FDA approval
Litigation
Reimbursement
Product recalls
Goodwill impairment
Tax

And 20 more.

Tracked managers holding both

Joel Greenblatt Gotham Asset Management 0.10% · 0.04%
Dodge & Cox Dodge & Cox 0.00% · 0.00%

Updated Sep 8, 2026 · the newer of the two companies' filings